Antisecretory factor in severe traumatic brain injury (AFISTBI): protocol for an exploratory randomized placebo-controlled trial

Antisecretory factor in severe traumatic brain injury (AFISTBI): protocol for an exploratory randomized placebo-controlled trial

Abstract Background Despite recent advances in neuroimaging and neurocritical care, severe traumatic brain injury (TBI) is still a major cause of severe disability and mortality, with increasing incidence worldwide. Antisecretory factor (AF), commercially available as Salovum®, has been shown to low...

Full description

Saved in:
Bibliographic Details
Main Authors: Linus Réen, David Cederberg, Niklas Marklund, Edward Visse, Peter Siesjö
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Trials
Online Access:https://doi.org/10.1186/s13063-025-08760-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items